Lipoprotein(a) is Robustly Associated with Aortic Valve Calcium

Overview

Journal Heart

Date 2021 May 8

PMID 33963048

Citations 17

Authors

Yannick Kaiser

Sunny S Singh

Kang H Zheng

Rutger Verbeek

Maryam Kavousi

Sara-Joan Pinto

Meike W Vernooij

Eric J G Sijbrands

S Matthijs Boekholdt

Yolanda B de Rijke

Erik S G Stroes

Daniel Bos

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the prevalence and quantity of aortic valve calcium (AVC) in two large cohorts, stratified according to age and lipoprotein(a) (Lp(a)), and to assess the association between Lp(a) and AVC.

Methods: We included 2412 participants from the population-based Rotterdam Study (52% women, mean age=69.6±6.3 years) and 859 apparently healthy individuals from the Amsterdam University Medical Centers (UMC) outpatient clinic (57% women, mean age=45.9±11.6 years). All individuals underwent blood sampling to determine Lp(a) concentration and non-enhanced cardiac CT to assess AVC. Logistic and linear regression analyses were performed to investigate the associations of Lp(a) with the presence and amount of AVC.

Results: The prevalence of AVC was 33.1% in the Rotterdam Study and 5.4% in the Amsterdam UMC cohort. Higher Lp(a) concentrations were independently associated with presence of AVC in both cohorts (OR per 50 mg/dL increase in Lp(a): 1.54 (95% CI 1.36 to 1.75) in the Rotterdam Study cohort and 2.02 (95% CI 1.19 to 3.44) in the Amsterdam UMC cohort). In the Rotterdam Study cohort, higher Lp(a) concentrations were also associated with increase in aortic valve Agatston score (β 0.19, 95% CI 0.06 to 0.32 per 50 mg/dL increase).

Conclusions: Lp(a) is robustly associated with presence of AVC in a wide age range of individuals. These results provide further rationale to assess the effect of Lp(a) lowering interventions in individuals with early AVC to prevent end-stage aortic valve stenosis.

Citing Articles

Novel Circulating Biomarkers in Aortic Valve Stenosis.

Ong J, Tan S, Koh A, Kong W, Sia C, Yeo T Int J Mol Sci. 2025; 26(5).

PMID: 40076529 PMC: 11899762. DOI: 10.3390/ijms26051902.

Aortic Valve Calcium Score: Applications in Clinical Practice and Scientific Research-A Narrative Review.

Gac P, Jaworski A, Grajnert F, Kicman K, Trejtowicz-Sutor A, Witkowski K J Clin Med. 2024; 13(14).

PMID: 39064103 PMC: 11277735. DOI: 10.3390/jcm13144064.

High lipoprotein(a): Actionable strategies for risk assessment and mitigation.

Reyes-Soffer G, Yeang C, Michos E, Boatwright W, Ballantyne C Am J Prev Cardiol. 2024; 18:100651.

PMID: 38646021 PMC: 11031736. DOI: 10.1016/j.ajpc.2024.100651.

Obesity: An Impact with Cardiovascular and Cerebrovascular Diseases.

Dutta S, Singhal A, Suryan V, Chandra N Indian J Clin Biochem. 2024; 39(2):168-178.

PMID: 38577137 PMC: 10987439. DOI: 10.1007/s12291-023-01157-w.

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?.

Tsioulos G, Kounatidis D, Vallianou N, Poulaki A, Kotsi E, Christodoulatos G Int J Mol Sci. 2024; 25(6).

PMID: 38542510 PMC: 10971284. DOI: 10.3390/ijms25063537.

References

Lindman B, Clavel M, Mathieu P, Iung B, Lancellotti P, Otto C . Calcific aortic stenosis. Nat Rev Dis Primers. 2016; 2():16006. PMC: 5127286. DOI: 10.1038/nrdp.2016.6. View

Capoulade R, Yeang C, Chan K, Pibarot P, Tsimikas S . Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018; 3(12):1212-1217. PMC: 6583098. DOI: 10.1001/jamacardio.2018.3798. View

Owens D, Katz R, Takasu J, Kronmal R, Budoff M, OBrien K . Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). Am J Cardiol. 2010; 105(5):701-8. PMC: 2829478. DOI: 10.1016/j.amjcard.2009.10.071. View

Zheng K, Tzolos E, Dweck M . Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. Cardiol Clin. 2019; 38(1):1-12. DOI: 10.1016/j.ccl.2019.09.010. View

Cao J, Steffen B, Budoff M, Post W, Thanassoulis G, Kestenbaum B . Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016; 36(5):1003-9. PMC: 4850093. DOI: 10.1161/ATVBAHA.115.306683. View

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

Pawade T, Clavel M, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L . Computed Tomography Aortic Valve Calcium Scoring in Patients With Aortic Stenosis. Circ Cardiovasc Imaging. 2018; 11(3):e007146. DOI: 10.1161/CIRCIMAGING.117.007146. View

Iung B, Vahanian A . Degenerative calcific aortic stenosis: a natural history. Heart. 2012; 98 Suppl 4:iv7-13. DOI: 10.1136/heartjnl-2012-302395. View

Greve A, Bang C, Boman K, Egstrup K, Forman J, Kesaniemi Y . Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol. 2018; 121(6):739-745. DOI: 10.1016/j.amjcard.2017.12.011. View

10.

Rossebo A, Pedersen T, Boman K, Brudi P, Chambers J, Egstrup K . Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359(13):1343-56. DOI: 10.1056/NEJMoa0804602. View

11.

Vliegenthart R, Oudkerk M, Hofman A, Oei H, van Dijck W, van Rooij F . Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation. 2005; 112(4):572-7. DOI: 10.1161/CIRCULATIONAHA.104.488916. View

12.

Cowell S, Newby D, Prescott R, Bloomfield P, Reid J, Northridge D . A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352(23):2389-97. DOI: 10.1056/NEJMoa043876. View

13.

Arsenault B, Boekholdt S, Dube M, Rheaume E, Wareham N, Khaw K . Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014; 7(3):304-10. DOI: 10.1161/CIRCGENETICS.113.000400. View

14.

Kamstrup P, Tybjaerg-Hansen A, Nordestgaard B . Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2013; 63(5):470-7. DOI: 10.1016/j.jacc.2013.09.038. View

15.

Zheng K, Tsimikas S, Pawade T, Kroon J, Jenkins W, Doris M . Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J Am Coll Cardiol. 2019; 73(17):2150-2162. PMC: 6494952. DOI: 10.1016/j.jacc.2019.01.070. View

16.

Thanassoulis G, Campbell C, Owens D, Smith J, Smith A, Peloso G . Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368(6):503-12. PMC: 3766627. DOI: 10.1056/NEJMoa1109034. View

17.

Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P . 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36):2739-2791. DOI: 10.1093/eurheartj/ehx391. View

18.

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

19.

Ikram M, Brusselle G, Murad S, Van Duijn C, Franco O, Goedegebure A . The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017; 32(9):807-850. PMC: 5662692. DOI: 10.1007/s10654-017-0321-4. View

20.

Verweij S, de Ronde M, Verbeek R, Boekholdt S, Planken R, Stroes E . Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. J Clin Lipidol. 2018; 12(3):597-603.e1. DOI: 10.1016/j.jacl.2018.02.007. View